INOVIO PHARMACEUTICALS, INC.·4

May 21, 4:11 PM ET

Weiner David B. 4

Research Summary

AI-generated summary

Updated

INO Director David B. Weiner Receives Equity Awards

What Happened

  • Director David B. Weiner was granted a total of 76,000 derivative awards on May 20, 2026: 41,800 option-type awards and 34,200 restricted stock units (RSUs). Both grants are reported at $0.00 per share in the Form 4 (derivative awards) and were issued under the company's 2023 Omnibus Incentive Plan as part of the non-employee director compensation policy. The options and RSUs each vest 100% on May 20, 2027.

Key Details

  • Transaction date: 2026-05-20; Filing date: 2026-05-21 (filed next day).
  • Awards: 41,800 derivatives (options) @ $0.00; 34,200 RSUs @ $0.00; total = 76,000 awards.
  • Vesting: Both the options and the RSUs vest 100% on May 20, 2027 (Footnotes F2, F3).
  • Plan/Policy: Granted under the 2023 Omnibus Incentive Plan pursuant to the issuer’s non-employee director compensation policy (Footnote F1).
  • Shares owned after transaction: Not specified in the Form 4 filing.
  • Timeliness: Filing appears timely (reported date 5/20/2026; filed 5/21/2026).

Context

  • These are compensation grants (not open-market purchases or sales). Options are derivative rights that, upon vesting and any required exercise, may convert into shares; RSUs represent a contingent right to receive one share each at vesting. Such awards are common for non-employee directors and reflect standard compensation rather than an express buy/sell signal.